Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386084534> ?p ?o ?g. }
- W4386084534 endingPage "9" @default.
- W4386084534 startingPage "1" @default.
- W4386084534 abstract "Exportin 1 (XPO1) inhibitors are being developed as a new agent for anti-cancer therapies. This study aimed to broadly portray the adverse event (AE) profile of selinexor, an XPO1 inhibitor, in actual clinical practice.Disproportionality analyses were conducted by calculating the information component and reporting odds ratio in VigiBase over different reporting periods. All selinexor-related AEs were classified by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities.A total of 116,443 AEs were identified in 2,608 patients that received selinexor. Patients with cardiac disorders had a higher propensity for death. Thirteen SOCs and 125 PTs were identified as having a potential connection with selinexor. Notably, 29 suspected signals detected in our study were defined as significant AEs by the European Medicines Agency, including febrile neutropenia, pancytopenia, and acute kidney injury. Attention should be paid to these AEs, despite most toxicities being manageable and reversible.This study highlights a number of AEs associated with selinexor. Most toxicities are reversible but require careful management. The benefit of selinexor still outweighs the potential risks, indicating XPO1 inhibitors as promising agents." @default.
- W4386084534 created "2023-08-24" @default.
- W4386084534 creator A5016808329 @default.
- W4386084534 creator A5017103752 @default.
- W4386084534 creator A5017439807 @default.
- W4386084534 creator A5027674411 @default.
- W4386084534 creator A5034654778 @default.
- W4386084534 creator A5047197050 @default.
- W4386084534 creator A5055528381 @default.
- W4386084534 creator A5067128808 @default.
- W4386084534 creator A5067508425 @default.
- W4386084534 creator A5069526411 @default.
- W4386084534 creator A5070391038 @default.
- W4386084534 creator A5091706843 @default.
- W4386084534 date "2023-08-22" @default.
- W4386084534 modified "2023-09-23" @default.
- W4386084534 title "Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase)" @default.
- W4386084534 cites W1967555951 @default.
- W4386084534 cites W1988100051 @default.
- W4386084534 cites W1996239270 @default.
- W4386084534 cites W2005366883 @default.
- W4386084534 cites W2015487160 @default.
- W4386084534 cites W2048561028 @default.
- W4386084534 cites W2062233810 @default.
- W4386084534 cites W2064130493 @default.
- W4386084534 cites W2064716383 @default.
- W4386084534 cites W2076346656 @default.
- W4386084534 cites W2118851558 @default.
- W4386084534 cites W2121229206 @default.
- W4386084534 cites W2122608040 @default.
- W4386084534 cites W2136670164 @default.
- W4386084534 cites W2146229086 @default.
- W4386084534 cites W2164046794 @default.
- W4386084534 cites W2167186282 @default.
- W4386084534 cites W2191554571 @default.
- W4386084534 cites W2330422482 @default.
- W4386084534 cites W2680325098 @default.
- W4386084534 cites W2771344728 @default.
- W4386084534 cites W2772881286 @default.
- W4386084534 cites W2785372400 @default.
- W4386084534 cites W2788392735 @default.
- W4386084534 cites W2794340145 @default.
- W4386084534 cites W2800882200 @default.
- W4386084534 cites W2805863842 @default.
- W4386084534 cites W2898184657 @default.
- W4386084534 cites W2901191795 @default.
- W4386084534 cites W2917569079 @default.
- W4386084534 cites W2938776515 @default.
- W4386084534 cites W2969931905 @default.
- W4386084534 cites W2975382763 @default.
- W4386084534 cites W3007177845 @default.
- W4386084534 cites W3008231845 @default.
- W4386084534 cites W3028886265 @default.
- W4386084534 cites W3037697670 @default.
- W4386084534 cites W3059759792 @default.
- W4386084534 cites W3087669131 @default.
- W4386084534 cites W3103404395 @default.
- W4386084534 cites W3105812043 @default.
- W4386084534 cites W3120455747 @default.
- W4386084534 cites W3138903175 @default.
- W4386084534 cites W3163518321 @default.
- W4386084534 cites W3168066833 @default.
- W4386084534 cites W3193337461 @default.
- W4386084534 cites W3204874652 @default.
- W4386084534 cites W3207790531 @default.
- W4386084534 cites W3209190780 @default.
- W4386084534 cites W3217692552 @default.
- W4386084534 cites W4282938358 @default.
- W4386084534 cites W4289594361 @default.
- W4386084534 doi "https://doi.org/10.1080/14740338.2023.2248888" @default.
- W4386084534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37608630" @default.
- W4386084534 hasPublicationYear "2023" @default.
- W4386084534 type Work @default.
- W4386084534 citedByCount "0" @default.
- W4386084534 crossrefType "journal-article" @default.
- W4386084534 hasAuthorship W4386084534A5016808329 @default.
- W4386084534 hasAuthorship W4386084534A5017103752 @default.
- W4386084534 hasAuthorship W4386084534A5017439807 @default.
- W4386084534 hasAuthorship W4386084534A5027674411 @default.
- W4386084534 hasAuthorship W4386084534A5034654778 @default.
- W4386084534 hasAuthorship W4386084534A5047197050 @default.
- W4386084534 hasAuthorship W4386084534A5055528381 @default.
- W4386084534 hasAuthorship W4386084534A5067128808 @default.
- W4386084534 hasAuthorship W4386084534A5067508425 @default.
- W4386084534 hasAuthorship W4386084534A5069526411 @default.
- W4386084534 hasAuthorship W4386084534A5070391038 @default.
- W4386084534 hasAuthorship W4386084534A5091706843 @default.
- W4386084534 hasConcept C17744445 @default.
- W4386084534 hasConcept C177713679 @default.
- W4386084534 hasConcept C197934379 @default.
- W4386084534 hasConcept C199539241 @default.
- W4386084534 hasConcept C2777105317 @default.
- W4386084534 hasConcept C2779473830 @default.
- W4386084534 hasConcept C57658597 @default.
- W4386084534 hasConcept C71924100 @default.
- W4386084534 hasConcept C98274493 @default.
- W4386084534 hasConceptScore W4386084534C17744445 @default.
- W4386084534 hasConceptScore W4386084534C177713679 @default.